Poseida Therapeutics WKN: A2PEYK ISIN: US73730P1084
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
Anzeige
![Smartbroker]()
Alles ab 0 Euro pro Order. Dauerhaft.
Schorsch11
vom 22.08.20 23:32 Uhr
https://www.fiercebiotech.com/biotech/poseida-shares-plunge-after-death-solid-car-t-trial-hold
Schorsch11
vom 22.08.20 23:26 Uhr
Net Losses
Net losses were $30.4 million and $59.2 million for the three and six months ended June 30, 2020, respectively, and $28.6 million and $42.0 million for the three and six months ended June 30, 2019, respectively.
Cash Position
As of June 30, 2020, we had cash, cash equivalents and short-term investments of $167.1 million. Net proceeds from the Company's IPO, which closed in July 2020, were $204.8 million
Schorsch11
vom 22.08.20 20:30 Uhr
Rebound-Kandidat:
Poseida Therapeutics, Inc. (NASDAQ:PSTX) shares closed the week down 34% to $8.61 on news its Phase 1 trial of P-PSMA-101 in metastatic castrate resistant prostate cancer patients has been placed on clinical hold due to a patient death arising from hepatic failure.
|
|
Kommentare | ||
|---|---|---|---|
| 1 | Hauptdiskussion |
Kursdetails
| Geld (bid) | 0,00 (0) |
|---|---|
| Brief (ask/offer) | 0,00 (0) |
| Spread | - |
| Geh. Stück | 0 |
| Eröffnung | 2,09 |
| Vortag | 2,09 |
| Tageshoch | 2,20 |
| Tagestief | 2,01 |
| 52W Hoch | 9,38 |
| 52W Tief | 1,75 |
Tagesvolumen
| in EUR gehandelt | 200 Stk |
|---|---|
| in USD gehandelt | 115 Tsd. Stk |
| Gesamt | 116 Tsd. Stk |
Anzeige
![Smartbroker]()
Der Broker von Deutschlands größter Finanzcommunity
Meldungen
- Putin warnt vor neuen Nato-Beitritten
- SMA Solar (S92) korrigieren, Nordex (NDX1) behauptet; Rivian (RIVN) und Tesla (TL0) tiefrot
- Silver X Mining Corp: Silver X meldet aktuelle Informationen zur Betriebstätigkeit im April
- Kein klarer Trend - Sorge vor Wachstumsabkühlung
- Osten gleichbehandeln - 'Klare Perspektive' für Leuna
Geld/Brief Kurse
| Börse | Geld | Brief | Zeit | Volumen | Kurs |
|---|---|---|---|---|---|
| Frankfurt | 2,06 | 2,14 | 1652685360 09:16 | 2,06 EUR | |
| Düsseldorf | 2,04 | 2,16 | 1652722252 19:30 | 1,98 EUR | |
| München | 2,08 | 2,10 | 1652680891 08:01 | 2,06 EUR | |
| Stuttgart | 2,04 | 2,14 | 1652723258 19:47 | 2,02 EUR | |
| Nasdaq | 2,18 | 2,19 | 1652729462 21:31 | 115.344 Stk | 2,18 USD |
| AMEX | 1652486400 14. May | 100 Stk | 2,17 USD | ||
| Tradegate | 2,06 | 2,08 | 1652692376 11:12 | 200 Stk | 2,12 EUR |
| London | 1652281992 11. May | 1,98 USD | |||
| Gettex | 2,04 | 2,12 | 1652730181 21:43 | 2,06 EUR | |
| Baader Bank | 2,04 | 2,12 | 1652730084 21:41 | 2,08 EUR | |
| TTMzero RT | 1652730315 21:45 | 2,07 EUR | ges. 115.644 Stk |
Realtime / Verzögert
Börsennotierung
| Marktkapitalisierung in EUR |
|---|
| 385,6 Mio. |
| Anzahl der Aktien |
| 62,7 Mio. |
Grundlegende Daten zur Poseida Therapeutics Aktie
| Finanzdaten | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e |
|---|---|---|---|---|---|---|---|
| KUV | - | - | - | - | - | - | - |
| Ergebnis je Aktie (bereinigt) | - | - | - | - | - | - | - |
| Cashflow | - | - | - | - | - | - | - |
| Eigenkapitalquote | - | - | - | - | - | - | - |
| Verschuldungsgrad | - | - | - | - | - | - | - |
| Eigenkapitalrendite | - | - | - | - | - | - | - |
| Gesamtkapitalrendite | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - |
| Fundamentaldaten | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e |
| KCV | - | - | - | - | - | - | - |
| Dividendenrendite | - | - | - | - | - | - | - |
| Kurs-Gewinn-Verhältnis (KGV) | - | - | - | - | - | - | - |
| Dividende je Aktie | - | - | - | - | - | - | - |
| Bilanzdaten | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e |
| Netto-Provisionsüberschuss | - | - | - | - | - | - | - |
| Umsatzerlöse | - | - | - | - | - | - | - |
| Ergebnis vor Steuern | - | - | - | - | - | - | - |
| Steuern | - | - | - | - | - | - | - |
| Ausschüttungssumme | - | - | - | - | - | - | - |
| Nettoverzinsung | - | - | - | - | - | - | - |
| Zinsertrag | - | - | - | - | - | - | - |
| Gesamtertrag | - | - | - | - | - | - | - |